Use of GabaB receptor agonists
View Patent ↗Novel compounds of formula I, with the exception of i) the racemate of (3-amino-2-hydroxypropyl)phosphinic acid; and ii) (2R/S, 3R)-(3-amino-2-hydroxybutyl)phosphinic acid, having affinity to one or more GABA B receptors, their pharmaceutically acceptable salts, solvates and stereoisomers, as well as processes for their preparation, pharmaceutical compositions containing said therapeutically active compounds and the use of said active compounds in therapy.
1. A method for inhibiting or treating irritable bowel syndrome (IBS), comprising administering to a subject in need thereof a pharmaceutically and pharmacologically effective amount of a compound of formula (I)
as well as a pharmaceutically acceptable salt, a solvate or an optical isomer thereof,
wherein
R 1 represents hydrogen;
R 2 represents hydroxy, fluoro or an oxo group;
R 3 represents hydrogen; and
R 4 represents hydrogen, lower alkyl or aryl, wherein the lower alkyl is optionally substituted with aryl,
with the exception of the racemate of (3-amino-2-hydroxypropyl) phosphinic acid.
2. The method according to claim 1 , wherein the compound administered is (3-amino-2-fluoropropyl)phosphinic acid.
3. The method according to claim 1 , wherein the compound administered is (2R)-(3-amino-2-fluoropropyl)phosphinic acid.
4. The method according to claim 1 , wherein the compound administered is (2S)-(3-amino-2-fluoropropyl)phosphinic acid.
5. The method according to claim 1 , wherein the compound administered is (3-amino-2-oxopropyl)phosphinic acid.
6. The method according to claim 1 , wherein the compound administered is (2S)-(3-amino-2-hydroxypropyl)phosphinic acid.
7. The method according to claim 1 , wherein the compound administered is (2R)-(3-amino-2-hydroxypropyl)phosphinic acid.